GLP-1 drugs, PCOS, and the fertility effect that needs a conversation

Polycystic ovary syndrome is usually described as a reproductive condition. Its drivers are largely metabolic: insulin resistance and excess weight suppress ovulation, cycles become irregular or stop, and fertility falls. Weight loss has been first-line advice for overweight women with PCOS for this reason, in the 2013 Endocrine Society guideline and again in the 2023 international guideline [1, 2]. GLP-1 drugs produce that weight loss reliably, and a less discussed consequence is pregnancy in women who believed they could not conceive.

Why the risk is easy to miss

Three assumptions collide. The patient assumes irregular cycles mean infertility, an assumption that may have held for years. Cycle-based contraception, if used, is calibrated to the old pattern. And the prescriber, often in a brief telehealth visit, may never ask about contraception.

The trial data show cycles changing within months of starting treatment. A 26-week randomized trial of liraglutide in 72 women with PCOS found more bleeding episodes in the treated group than with placebo, alongside 5.2 kg more weight loss [3]. A 2023 meta-analysis of 11 randomized trials (840 women) found better menstrual regularity and a higher natural pregnancy rate with GLP-1 drugs (relative risk 1.72) [4]. Ovulation itself was not measured in most of these trials, so the exact timing of its return is not known [4]. What the trials do show is consistent with fertility returning before any weight goal is reached, and a first ovulation can come before a woman notices any change in her cycle.

What the reports show

News coverage began in 2024, when women posted on TikTok about unplanned pregnancies on semaglutide and tirzepatide and the term "Ozempic babies" spread [5]. The published data since then are observational.

An Australian general-practice study in the Medical Journal of Australia followed 18,010 women aged 18 to 49 who were first prescribed a GLP-1 drug between 2011 and 2022. At the time of the prescription, 21.2 percent had documented contraception, and 2.2 percent were pregnant within six months [6]. By 2022, about nine in ten new prescriptions in this age group went to women without diabetes [6].

On outcomes, a 2026 meta-analysis in the journal Med pooled 10 observational studies covering 2,118,215 pregnancies, 8,325 of them with GLP-1 exposure in the six months before a positive pregnancy test. It found no detectable increase in miscarriage, stillbirth, congenital anomalies, or preterm birth. The authors wrote that this is not evidence of safety in pregnancy and does not change the advice to stop before a planned pregnancy [7]. A 2026 claims analysis of 3,572 US pregnancies in Annals of Internal Medicine compared continuing a GLP-1 drug into the first trimester with stopping it and found similar rates of non-live birth (29.7 versus 27.1 percent), with estimates for major malformations too imprecise to settle the question [8].

The same physiology has a welcome side. For women with PCOS who want to conceive, these drugs accomplish what metformin did weakly. In a 2015 meta-analysis of 12 randomized trials, metformin added to lifestyle change lowered BMI by 0.73 kg/m² over six months compared with lifestyle alone, and metformin by itself did no better than lifestyle plus placebo [9].

What planning requires

The FDA labels for Ozempic and Wegovy advise stopping semaglutide at least two months before a planned pregnancy because of its long washout period; animal studies showed fetal harm, and the drugs are not recommended in pregnancy [10, 11]. Tirzepatide carries a separate warning: it can reduce absorption of oral contraceptives, so the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase [12].

Folate matters on the same timeline. The neural tube closes within the first month after conception, around day 28, usually before a pregnancy is recognized [13]. This is why the CDC advises 400 micrograms of folic acid daily for all women aged 15 to 45 who could become pregnant, starting at least a month before conception, and not only for those actively trying [14]. The MRC Vitamin Study, a randomized trial published in The Lancet in 1991, showed a 72 percent reduction in neural tube defects with 4 mg of folic acid daily in women who had a previous affected pregnancy (relative risk 0.28) [15]. The timing argument has not changed since.

A complete prescribing conversation for a woman of reproductive age covers three items: fertility may return during treatment even after years of irregular cycles; contraception should not rely on cycle tracking while cycles are changing, and oral contraceptives need a backup method on tirzepatide; and a planned pregnancy should trigger a preconception visit, a stop date for the drug, and folate in advance.

Interpretation

Restored fertility on GLP-1 therapy follows from the drug working as intended on the metabolic drivers of PCOS and obesity-related anovulation. The published data so far show low documented contraception use at the time of prescribing, a measurable pregnancy rate within six months, and no detected increase in harm from exposure around conception, with the caveat that all of it is observational and the labels still say to stop two months before trying.

Sources

1. Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 2013;98(12):4565-4592. doi:10.1210/jc.2013-2350
2. Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463
3. Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive BioMedicine Online, 2017;35(1):121-127. doi:10.1016/j.rbmo.2017.03.023
4. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders, 2023;23:245. doi:10.1186/s12902-023-01500-5
5. Fox News, April 16, 2024. "Ozempic babies: Women claim weight-loss drugs are making them more fertile and experts agree." https://www.foxnews.com/health/ozempic-babies-women-claim-weight-loss-drugs-fertile-experts-agree. Healthline, "Ozempic babies: unplanned pregnancies." https://www.healthline.com/health-news/ozempic-babies-unplanned-pregnancies
6. Thapaliya et al. Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011-2022. Medical Journal of Australia, 2025. doi:10.5694/mja2.70026
7. D'Antonio F, et al. GLP-1 receptor agonist exposure in the periconceptional period and adverse obstetric outcomes: a systematic review and meta-analysis. Med, 2026. doi:10.1016/j.medj.2026.101267
8. Huybrechts KF, et al. Target trial emulation of GLP-1 receptor agonist continuation into the first trimester, US insurance claims 2011 to 2024. Annals of Internal Medicine, 2026. doi:10.7326/ANNALS-25-04820 (title paraphrased and author order to be confirmed against the journal record)
9. Naderpoor N, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update, 2015;21(5):560-574. doi:10.1093/humupd/dmv025
10. Ozempic (semaglutide) injection, US prescribing information, Novo Nordisk, section 8.3: discontinue at least 2 months before a planned pregnancy. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
11. Wegovy (semaglutide) injection, US prescribing information, Novo Nordisk, section 8.3: discontinue at least 2 months before a planned pregnancy because of the long half-life of semaglutide.
12. Eli Lilly Medical Information. Can adults with obesity or overweight taking Zepbound also take oral contraceptives? https://medical.lilly.com/us/products/answers/can-adults-with-obesity-or-overweight-taking-zepbound-also-take-oral-contraceptives-211019
13. Centers for Disease Control and Prevention. Folic acid: key findings, are women getting enough folic acid? (neural tube defects occur in the first month of pregnancy). https://www.cdc.gov/ncbddd/folicacid/features/kf-women-enough-folic-acid.html. Review article, PubMed Central: neural tube closure is usually complete by 28 days post-conception. https://pmc.ncbi.nlm.nih.gov/articles/PMC3137839
14. Centers for Disease Control and Prevention. CDC's work to understand and prevent neural tube defects: 400 mcg folic acid daily for women aged 15 to 45, starting at least one month before pregnancy. https://www.cdc.gov/NCBDDD/folicacid/aboutus.html
15. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. The Lancet, 1991;338(8760):131-137. PMID 1677062. https://pubmed.ncbi.nlm.nih.gov/1677062/